Developing a vaccine and immunotherapy for Coccidioidomycosis
Official title: Project #3:Active Vaccination and Immunotherapy Against Coccidioidomycosis
Funded at University of Texas San Antonio · NIH-11004672 · Data updated 2026-11-12
This study is working on a new vaccine and treatment for Coccidioidomycosis, a fungal infection that affects many people in the U.S., to help boost your immune system and keep you healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $271,399 |
| NIH project number | 5U19AI166761-04 |
| Project ID | NIH-11004672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Coccidioidomycosis, particularly those living in endemic areas or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for Coccidioidomycosis or those with existing severe allergic reactions to vaccine components may not benefit from this research.
What this research studies
This research focuses on creating a vaccine and immunotherapy for Coccidioidomycosis, a fungal infection affecting around 350,000 people in the U.S. each year. The team has developed a recombinant chimeric polypeptide antigen that is designed to stimulate a strong immune response. They will explore two delivery methods, mRNA and vector-based systems, to enhance the immune system's ability to fight the infection. The goal is to produce a safe and effective vaccine that can be tested in humans.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence and severity of Coccidioidomycosis.
How similar studies have gone: Previous research has shown promise in developing vaccines for fungal infections, but this specific approach using rCpa1 is novel.
Where this research is happening
-
University of Texas San Antonio
San Antonio, United States Active
Researchers
- Principal investigator: Hung, Chiung-Yu — University of Texas San Antonio
- Study coordinator: Hung, Chiung-Yu
Related research
Other NIH-funded projects on the same topics.
-
Personalized tumor vaccine plus immune blockers for glioblastoma
This project explores whether combining a patient's own tumor‑based vaccine with two immune‑blocking drugs can help people with glioblastoma.
-
Targeting brain cancer resistance with dendritic cell vaccination and PD-1/CSF-1R inhibition
This grant supports a brain cancer study that tests a vaccine-based immunotherapy combined with checkpoints and myeloid-cell blockade to help glioblastoma patients live longer.
-
COVID-19 vaccine responses in kidney transplant patients taking mycophenolate
This project looks at how the anti-rejection drug mycophenolate affects COVID-19 vaccine protection in people with kidney transplants.
-
Vaccine and immune therapy for Valley fever (coccidioidomycosis)
Testing new vaccine approaches that teach the immune system to protect people at risk of Valley fever.
-
Improving Immunotherapy for Brain Cancer
This research explores new ways to make immunotherapy more effective for people with glioblastoma, a type of brain cancer, by overcoming treatment resistance.
-
Investigating immune responses to COVID-19 vaccination in children with multiple sclerosis on immunotherapy
This study is looking at how different treatments for multiple sclerosis affect how well kids respond to COVID-19 vaccines, so we can better understand how to protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.